Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 17.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 06.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 05.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 01.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 06.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 23.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
Stammdaten
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Unternehmen & Branche
| Name | AVITA Medical, Inc. |
|---|---|
| Ticker | RCEL |
| CIK | 0001762303 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 102,7 Mio. USD |
| Beta | 1,89 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 71,610,000 | -48,587,000 | -1.74 | 56,392,000 | -16,650,000 |
| 2025-09-30 | 10-Q | 17,062,000 | -13,187,000 | -0.46 | 63,728,000 | -6,666,000 |
| 2025-06-30 | 10-Q | 18,418,000 | -9,920,000 | -0.38 | 58,134,000 | -12,892,000 |
| 2025-03-31 | 10-Q | 18,514,000 | -13,859,000 | -0.53 | 69,556,000 | -4,571,000 |
| 2024-12-31 | 10-K | 64,251,000 | -61,845,000 | -2.39 | 79,711,000 | 4,499,000 |
| 2024-09-30 | 10-Q | 19,546,000 | -16,205,000 | -0.62 | 81,051,000 | 12,227,000 |
| 2024-06-30 | 10-Q | 15,195,000 | -15,393,000 | -0.60 | 87,826,000 | 23,915,000 |
| 2024-03-31 | 10-Q | 11,104,000 | -18,658,000 | -0.73 | 97,381,000 | 32,569,000 |
| 2023-12-31 | 10-K | 50,143,000 | -35,381,000 | -1.40 | 111,640,000 | 49,056,000 |
| 2023-09-30 | 10-Q | 13,645,000 | -8,712,000 | -0.34 | 81,014,000 | 62,978,000 |
| 2023-06-30 | 10-Q | 11,753,000 | -10,384,000 | -0.41 | 86,330,000 | 68,647,000 |
| 2023-03-31 | 10-Q | 10,550,000 | -9,220,000 | -0.37 | 92,622,000 | 77,561,000 |
| 2022-12-31 | 10-K | 34,421,000 | -26,665,000 | 1.07 | 98,264,000 | 84,740,000 |
| 2022-09-30 | 10-Q | 9,092,000 | -5,588,000 | 0.22 | 99,932,000 | 87,986,000 |
| 2022-06-30 | 10-Q | 8,335,000 | -6,261,000 | 0.25 | 102,669,000 | 92,560,000 |
| 2022-03-31 | 10-Q | 7,539,000 | -9,463,000 | 0.38 | 106,491,000 | 97,815,000 |
| 2021-12-31 | 10-K | 13,956,000 | -14,427,000 | 0.58 | 116,015,000 | 104,624,000 |
| 2021-09-30 | 10-Q | 7,020,000 | -5,948,000 | 0.24 | 121,173,000 | 111,492,000 |
| 2021-06-30 | 10-Q | 10,304,000 | -4,718,000 | 0.19 | 125,501,000 | 115,655,000 |
| 2021-06-30 | 10-K | 10,304,000 | -4,718,000 | -0.19 | 125,501,000 | 115,655,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | O'Toole David D | Officer, CFO | Open Market Purchase | 1,800 | 4.78 | 8,604.00 | +38,3% | |
| 2026-02-19 | O'Toole David D | Officer, CFO | Open Market Purchase | 3,000 | 4.15 | 12,450.00 | +55,5% | |
| 2025-08-28 | McNamara Robert | Director | Open Market Purchase | 10,000 | 4.50 | 45,000.00 | +200,4% | |
| 2025-08-26 | O'Toole David D | Officer, CFO | Open Market Purchase | 2,000 | 4.52 | 9,040.00 | +40,3% | |
| 2025-08-19 | McNamara Robert | Director | Open Market Purchase | 10,000 | 5.00 | 50,000.00 | +222,7% | |
| 2025-08-12 | O'Toole David D | Officer, CFO | Open Market Purchase | 2,000 | 4.81 | 9,620.00 | +42,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.